Tiba joined Novo Ventures (US) Inc. in San Francisco, California in 2010.
She is a member of the Board of directors of Spruce Biosciences, Mirum Pharmaceuticals, Avalyn Biosciences, Nkarta Therapeutics, Arcellx Inc, MDLive, and Aristea Therapeutics. She previously served as board member for AnaptysBio (IPO 2017), iRhtyhm Technologies (IPO 2016), and Cianna Medical (acquired 2018).Tiba has more than 20years of research, banking, and venture experience in life sciences that spans various therapeutic areas and technology platforms. Prior to joining Novo Ventures (US) Inc., Tiba was a Director with Burrill & Company where she has completed regional and cross-border M&A, licensing, and financing transactions for biotech and large pharmaceutical companies.
Tiba received her PhD from the Graduate Group in Biophysics at the University of California, San Francisco where her research involved developing computational methods for drug discovery. She has an undergraduate degree in physics from the University of California, Irvine. Tiba is also a published author of scientific articles and book chapters in the area of rational drug design.